Abstract: Oral formulations comprising one or more proteasome inhibitors for use as a treatment of coronavirus infection in a subject. Also disclosed are the use of such for the treatment or prevention of SARS-CoV-2 infection in humans.

Abstract: A tyrosine kinase inhibitor for use in the treatment of COVID-19 and/or its associated symptoms. Also disclosed is a method of treating an individual infected with a coronavirus, wherein said method comprises the steps of: providing a tyrosine kinase inhibitor; and administering said tyrosine kinase inhibitor to said individual in a dosage amount sufficient to prevent/stabilize/reduce the risks and/or symptoms associated with a coronavirus infection.

Abstract: Systems, methods, and non-transitory computer-readable storage media for identifying potential therapeutics for pathogens (bacterial or viral). The system can receive a plurality of molecules known to have interactions with a pathogen, fragment the plurality of molecules into a plurality of linkers and a plurality of rigids, and remove redundancies from the plurality of linkers and the plurality of rigids. The system can then identify a plurality of possible molecules formed from the fragments, evaluate those possible molecules for toxicity, and analyze the non-toxic candidates using a convolutional neural network associated with the pathogen. The final candidates can then be used for in-vivo testing.

Abstract: A method, computer-readable medium, and system for identifying compounds from chemical libraries that can be used for the therapeutic treatment of a disease or used as lead compounds in a drug development program. In particular, information from homologous proteins is used to predict, for a target protein, molecular functions that can be used to screen libraries of compounds for individual compounds that are predicted to have high binding affinities for the target protein.